Boston Scientific

At a glance

Boston Scientific reported 2025 revenue of $20.07B, up 19.9% from $16.75B in 2024. Over 4 years since 2021 ($11.89B), that is growth of about 14% a year. Operating margin was 18%, up from 10.1% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 8 insiders reported 8 open-market purchases ($10M) and 4 sales ($23M). All of the sales were made under pre-arranged 10b5-1 trading plans. The largest was a sale of $15M by Chairman, President & CEO Michael F Mahoney on Feb 3, 2026. Net, insiders were sellers of $13M.

Boston Scientific filed 19 current reports (Form 8-K) in the last 12 months, most often for officer or director change (5), results of operations (4), other events (4) and material agreement (2). The latest officer or director change was reported on Oct 7, 2026. It reported a material agreement or a completed acquisition or disposal 2 times.

3 of the 20 investors tracked here held Boston Scientific at the last quarter end, worth $290.8M combined. It is the largest weight for Renaissance Technologies (0.1% of its portfolio), followed by National Pension Service (Korea) (0.1%). Added: National Pension Service (Korea) and Bridgewater Associates. Reduced: Renaissance Technologies.

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.